155 related articles for article (PubMed ID: 38022396)
1. Vasopressin Analog [V
Sobol NT; Solerno LM; Llavona C; Alonso DF; Garona J
World J Oncol; 2023 Dec; 14(6):540-550. PubMed ID: 38022396
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer.
Garona J; Sobol NT; Pifano M; Segatori VI; Gomez DE; Ripoll GV; Alonso DF
Cancer Res Treat; 2019 Apr; 51(2):438-450. PubMed ID: 29879760
[TBL] [Abstract][Full Text] [Related]
3. Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.
Garona J; Pifano M; Pastrian MB; Gomez DE; Ripoll GV; Alonso DF
Clin Exp Metastasis; 2016 Aug; 33(6):589-600. PubMed ID: 27146156
[TBL] [Abstract][Full Text] [Related]
4. Development and therapeutic potential of vasopressin synthetic analog [V
Garona J; Pifano M; Ripoll G; Alonso DF
Vitam Horm; 2020; 113():259-289. PubMed ID: 32138951
[TBL] [Abstract][Full Text] [Related]
5. Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma.
Sobol NT; Solernó LM; Beltrán B; Vásquez L; Ripoll GV; Garona J; Alonso DF
Exp Ther Med; 2021 Jun; 21(6):566. PubMed ID: 33850538
[TBL] [Abstract][Full Text] [Related]
6. The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.
Garona J; Pifano M; Orlando UD; Pastrian MB; Iannucci NB; Ortega HH; Podesta EJ; Gomez DE; Ripoll GV; Alonso DF
Int J Oncol; 2015; 46(6):2335-45. PubMed ID: 25846632
[TBL] [Abstract][Full Text] [Related]
7. Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.
Pifano M; Garona J; Capobianco CS; Gonzalez N; Alonso DF; Ripoll GV
Front Oncol; 2017; 7():11. PubMed ID: 28194370
[TBL] [Abstract][Full Text] [Related]
8. Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer.
Ripoll GV; Garona J; Hermo GA; Gomez DE; Alonso DF
Anticancer Res; 2010 Dec; 30(12):5049-54. PubMed ID: 21187489
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells.
Iannucci NB; Ripoll GV; Garona J; Cascone O; Ciccia GN; Gomez DE; Alonso DF
Future Med Chem; 2011 Dec; 3(16):1987-93. PubMed ID: 22098349
[TBL] [Abstract][Full Text] [Related]
10. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
11. Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.
Ripoll GV; Garona J; Pifano M; Farina HG; Gomez DE; Alonso DF
Breast Cancer Res Treat; 2013 Nov; 142(1):9-18. PubMed ID: 24122393
[TBL] [Abstract][Full Text] [Related]
12. The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study.
Alalikhan A; Ebrahimi S; Aliee A; Mirzavi F; Hashemy SI
Med Oncol; 2024 Feb; 41(3):70. PubMed ID: 38340190
[TBL] [Abstract][Full Text] [Related]
13. Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
Kong L; Wang X; Zhang K; Yuan W; Yang Q; Fan J; Wang P; Liu Q
PLoS One; 2015; 10(9):e0137888. PubMed ID: 26368019
[TBL] [Abstract][Full Text] [Related]
14. The Anticancer Effects of the Pro-Apoptotic Benzofuran-Isatin Conjugate (5a) Are Associated With p53 Upregulation and Enhancement of Conventional Chemotherapeutic Drug Efficiency in Colorectal Cancer Cell Lines.
Vaali-Mohammed MA; Abdulla MH; Matou-Nasri S; Eldehna WM; Meeramaideen M; Elkaeed EB; El-Watidy M; Alhassan NS; Alkhaya K; Al Obeed O
Front Pharmacol; 2022; 13():923398. PubMed ID: 36046830
[TBL] [Abstract][Full Text] [Related]
15. Demethylzeylasteral Exerts Antitumor Effects
Liu G; Lai D; Jiang Y; Yang H; Zhao H; Zhang Y; Liu D; Pang Y
Anticancer Agents Med Chem; 2022; 22(5):851-863. PubMed ID: 34102996
[TBL] [Abstract][Full Text] [Related]
16. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation.
Xavier CP; Lima CF; Rohde M; Pereira-Wilson C
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1449-57. PubMed ID: 21479885
[TBL] [Abstract][Full Text] [Related]
17.
Huang CY; Chien JH; Chang KF; Hsiao CY; Huang YC; Chen YT; Hsu MY; Hsieh MC; Tsai NM
Food Sci Nutr; 2022 May; 10(5):1638-1648. PubMed ID: 35592288
[No Abstract] [Full Text] [Related]
18. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
[TBL] [Abstract][Full Text] [Related]
19. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
20. LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer.
Jiang Z; Li L; Hou Z; Liu W; Wang H; Zhou T; Li Y; Chen S
Cell Signal; 2020 Feb; 66():109483. PubMed ID: 31760170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
